Audit Programme Management in Pharmacovigilance

Introduction

Individual audits provide assurance regarding specific activities.

Audit programmes provide assurance regarding the pharmacovigilance system as a whole.

This distinction is important.

An organisation may perform excellent individual audits while still lacking a coherent strategy for assessing overall system effectiveness.

Audit programme management provides that strategy.

It ensures that audit activities are:

• Planned
• Risk-based
• Coordinated
• Governed
• Sustainable

Without a structured programme, audit activities often become reactive and fragmented.

What Is an Audit Programme?

An audit programme is the framework used to plan, manage and oversee audit activities across the pharmacovigilance system.

It defines:

• What will be audited
• Why it will be audited
• When it will be audited
• How frequently it will be audited
• How results will be managed

A useful definition is:

An audit programme is the organised system through which pharmacovigilance audits are planned, executed and monitored.

Why Audit Programmes Matter

Modern pharmacovigilance systems are complex.

They may include:

• Global operations
• Multiple affiliates
• Numerous vendors
• Technology platforms
• Diverse regulatory obligations

It is rarely possible to audit everything every year.

Choices must be made.

Audit programmes help organisations allocate resources where they provide the greatest value.

Regulatory Expectations

Regulators generally expect pharmacovigilance audits to be:

• Risk-based
• Independent
• Documented
• Systematic

An audit programme helps demonstrate these characteristics.

Inspectors frequently review:

• Audit plans
• Audit schedules
• Risk assessments
• Governance records
• Programme effectiveness

The objective is to determine whether audit activities are managed appropriately.

The Audit Universe

The audit universe represents the collection of activities that may be audited.

Examples include:

Core Pharmacovigilance Activities

• Case processing
• Literature surveillance
• Signal management
• Aggregate reporting

Governance Activities

• QPPV oversight
• Escalation processes
• Compliance monitoring

Quality System Activities

• CAPAs
• Deviations
• Training
• Documentation management

Vendor Activities

• Outsourced pharmacovigilance services
• Technology providers
• Safety database vendors

Affiliate Activities

• Local pharmacovigilance systems
• Country operations

The audit universe provides the foundation for programme planning.

Building the Audit Universe

An effective audit universe should be:

Complete

Significant activities should be represented.

Current

Reflect current operating models.

Risk-Oriented

Support prioritisation activities.

Maintainable

Easy to review and update.

The audit universe should evolve as the pharmacovigilance system evolves.

Risk-Based Planning

Risk assessment is the cornerstone of modern audit programmes.

A useful principle is:

Audit effort should be proportional to risk.

Common risk factors include:

Patient Safety Impact

Potential effect on patient protection.

Regulatory Impact

Potential effect on compliance.

Operational Complexity

Complex processes often create greater risk.

Outsourcing Dependency

Critical vendors may require additional attention.

Historical Performance

Previous findings may indicate elevated risk.

Inspection History

Past inspection outcomes may influence priorities.

For additional discussion see:

[[risk-based-audit-planning]]

Annual Audit Plans

Many organisations develop annual audit plans.

These plans typically define:

• Planned audits
• Scope
• Timing
• Resources
• Objectives

Annual plans help ensure transparency and accountability.

However, plans should remain flexible enough to accommodate emerging risks.

Multi-Year Audit Strategies

A single year rarely provides sufficient coverage of the entire audit universe.

Consequently, many organisations maintain multi-year strategies.

Benefits include:

• Broader coverage
• Better resource planning
• Improved risk management
• Greater consistency

A multi-year view often improves programme maturity.

Programme Governance

Audit programmes require governance.

Typical governance responsibilities include:

• Plan approval
• Resource allocation
• Escalation decisions
• Programme review
• Risk evaluation

Strong governance helps ensure programme effectiveness.

Audit Independence

Independence is a fundamental audit principle.

Auditors should not assess activities for which they are directly responsible.

Independence supports:

• Credibility
• Objectivity
• Reliability

Without independence, audit conclusions may be questioned.

Resource Management

Audit programmes depend upon sufficient resources.

Considerations include:

• Auditor availability
• Auditor competence
• Subject matter expertise
• Budget
• Technology support

Resource limitations frequently influence programme effectiveness.

Competency Management

Effective auditors require appropriate knowledge and skills.

Areas may include:

• Pharmacovigilance regulations
• Audit methodologies
• Risk management
• Interview techniques
• Root cause analysis

Competency development should be an ongoing activity.

Audit Scheduling

Scheduling should balance:

• Risk priorities
• Resource availability
• Operational realities

Excessive rigidity may reduce flexibility.

Excessive flexibility may reduce accountability.

Effective programmes balance both.

Managing Emerging Risks

Audit programmes should not be static.

Examples of emerging risks include:

• Regulatory changes
• Major deviations
• Inspection findings
• New vendors
• Organisational restructuring

Mature programmes adjust priorities when necessary.

Programme Metrics

Audit programmes should be monitored.

Examples include:

Audit Coverage

Planned versus completed audits.

Schedule Adherence

Timeliness of execution.

Finding Trends

Patterns across audits.

CAPA Performance

Closure and effectiveness.

Repeat Findings

Recurrence of previously identified issues.

Metrics support programme improvement.

The QPPV Perspective

Audit programmes provide an important source of assurance for the QPPV.

The QPPV may use programme outputs to understand:

• Emerging risks
• Compliance concerns
• Governance weaknesses
• Vendor performance

Strong audit programmes therefore support effective oversight.

Inspection Perspective

Inspectors frequently evaluate:

• Programme structure
• Risk assessments
• Audit coverage
• CAPA management
• Governance arrangements

A common question is:

Does the programme provide meaningful assurance regarding the pharmacovigilance system?

The answer should be supported by evidence.

Common Programme Weaknesses

Recurring weaknesses include:

No Formal Audit Universe

Coverage decisions become inconsistent.

Weak Risk Assessment

Resources are allocated poorly.

Static Plans

Emerging risks are ignored.

Resource Constraints

Important audits are deferred repeatedly.

Weak Governance

Findings do not influence decision-making.

Repeat Findings

The same issues recur over time.

These weaknesses reduce assurance significantly.

Characteristics of Mature Audit Programmes

High-performing organisations generally demonstrate:

Risk-Based Planning

Resources align with risk.

Strong Governance

Programme decisions are structured.

Effective Resource Management

Competent auditors are available.

Flexibility

Emerging risks can be addressed.

Continuous Improvement

The programme evolves over time.

QPPV Visibility

Important information reaches pharmacovigilance leadership.

These characteristics contribute to sustainable assurance.

Key Takeaways

• Audit programmes provide assurance regarding the pharmacovigilance system as a whole.
• The audit universe forms the foundation of programme planning.
• Risk-based planning should drive audit priorities.
• Annual and multi-year planning both play important roles.
• Independence is essential for credibility.
• Audit programmes should adapt to emerging risks.
• Programme metrics help support continuous improvement.
• Mature audit programmes are structured, risk-based and governance-driven.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module IV – Pharmacovigilance Audits.
2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
4. Regulation (EC) No 726/2004.
5. Directive 2001/83/EC.
6. Commission Implementing Regulation (EU) No 520/2012.
7. ICH Q9 Quality Risk Management.
8. ICH E2E Pharmacovigilance Planning.